Should I buy or sell BioCardia stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioCardia in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" BCDA shares. View BCDA analyst ratings or view top-rated stocks .

What is BioCardia's stock price target for 2024?

2 analysts have issued 1 year target prices for BioCardia's shares. Their BCDA share price targets range from $4.00 to $4.00. On average, they predict the company's stock price to reach $4.00 in the next twelve months. This suggests a possible upside of 974.1% from the stock's current price. View analysts price targets for BCDA or view top-rated stocks among Wall Street analysts .

How have BCDA shares performed in 2024?

BioCardia's stock was trading at $0.6642 on January 1st, 2024. Since then, BCDA shares have decreased by 43.9% and is now trading at $0.3724. View the best growth stocks for 2024 here .

Are investors shorting BioCardia?

BioCardia saw a decline in short interest during the month of March. As of March 31st, there was short interest totaling 535,900 shares, a decline of 46.9% from the March 15th total of 1,010,000 shares. Based on an average trading volume of 372,500 shares, the days-to-cover ratio is currently 1.4 days. View BioCardia's Short Interest .

When is BioCardia's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our BCDA earnings forecast .

How were BioCardia's earnings last quarter?

BioCardia, Inc. (NASDAQ:BCDA) announced its earnings results on Wednesday, November, 10th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.21) by $0.05. The company had revenue of $0.82 million for the quarter, compared to analysts' expectations of $0.04 million. BioCardia had a negative trailing twelve-month return on equity of 3,638.68% and a negative net margin of 2,425.79%. During the same period in the prior year, the firm posted ($0.30) earnings per share.

When did BioCardia's stock split?

BioCardia shares reverse split before market open on Friday, November 3rd 2017. The 1-12 reverse split was announced on Thursday, November 2nd 2017. The number of shares owned by shareholders was adjusted after the market closes on Thursday, November 2nd 2017. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.

What other stocks do shareholders of BioCardia own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioCardia investors own include Arotech (ARTX) , CytoDyn (CYDY) , China Gold International Resources (CGG) , BioSolar (BSRC) , Blink Charging (BLNK) , Aurcana Silver (AUNFF) , RecycLiCo Battery Materials (AMY) and

When did BioCardia IPO?

BioCardia (BCDA) raised $51 million in an IPO on the week of July 20th 2015. The company issued 3,900,000 shares at $12.00-$14.00 per share. Cantor Fitzgerald & Co. acted as the underwriter for the IPO and Roth Capital Partners and Maxim Group were co-managers.

How do I buy shares of BioCardia?

Shares of BCDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:BCDA

BioCardia (BCDA) Stock Price, News & Analysis

→ Trump’s “Tax Free” Retirement Strategy (From Gold Safe Exchange) (Ad)

Free BCDA Stock Alerts

$0.37

-0.02 (-5.10%)

(As of 04/15/2024 ET)

Compare

Today's Range: $0.37
▼
$0.40
50-Day Range: $0.37
▼
$0.58
52-Week Range: $0.36
▼
$2.92

Volume: 117,285 shs
Average Volume: 130,304 shs
Market Capitalization: $9.95 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $4.00

Get BioCardia alerts:

BioCardia MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.50 Rating Score
Upside/Downside: 974.1% Upside
$4.00 Price Target
Short Interest: Healthy
2.00% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 1.44
Based on 2 Articles This Week
Insider Trading: Balanced
Insiders Both Buying and Selling
Proj. Earnings Growth: Decreasing
From ($0.42) to ($0.49) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.76 out of 5 stars

Medical Sector

423rd out of 928 stocks

Biological Products, Except Diagnostic Industry

62nd out of 152 stocks

3.3

Analyst's Opinion

Consensus Rating
BioCardia has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.
Amount of Analyst Coverage
BioCardia has received no research coverage in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
2.00% of the outstanding shares of BioCardia have been sold short.
Short Interest Ratio / Days to Cover
BioCardia has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in BioCardia has recently decreased by 46.94%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
BioCardia does not currently pay a dividend.
Dividend Growth
BioCardia does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for BCDA.

3.0

News and Social Media Coverage

News Sentiment
BioCardia has a news sentiment score of 1.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.66 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for BioCardia this week, compared to 1 article on an average week.
MarketBeat Follows
Only 1 people have added BioCardia to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, BioCardia insiders have sold just slightly more of their company's stock than they have bought. Specifically, they have bought $49,925.00 in company stock and sold $55,815.00 in company stock. It is common for insiders to sell company stock at intervals simply to diversify their holdings.
Percentage Held by Insiders
23.90% of the stock of BioCardia is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 20.57% of the stock of BioCardia is held by institutions.

0.0

Earnings and Valuation

Earnings Growth
Earnings for BioCardia are expected to decrease in the coming year, from ($0.42) to ($0.49) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of BioCardia is -0.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of BioCardia is -0.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

Ad Gold Safe Exchange

Trump’s “Tax Free” Retirement Strategy

Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.

Protect your retirement savings from the inevitable devaluation of the dollar…

About BioCardia Stock (NASDAQ:BCDA)

BioCardia, Inc., a clinical-stage regenerative medicine company, engages in development of cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP, an autologous mononuclear cell therapy system for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease. The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic heart failure. In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart; and Morph deflectable guides and sheaths. The company is based in Sunnyvale, California.

BCDA Stock Price History

30 days | 90 days | 365 days | Advanced Chart

BCDA Stock News Headlines

April 1, 2024 | finance.yahoo.com

BioCardia, Inc. (NASDAQ:BCDA) Q4 2023 Earnings Call Transcript

March 29, 2024 | finanznachrichten.de

BioCardia, Inc.: BioCardia Reports Fourth Quarter and Full Year 2023 Business Highlights and Financial Results

April 16, 2024 | InvestorPlace (Ad)

REVEALED: Elon Musk’s Secret A.I. Facility?

I recently shot this video outside what could be Elon Musk’s biggest secret. What’s happening inside these walls is so important that our government has declared it a matter of national security.

March 29, 2024 | finance.yahoo.com

BioCardia Full Year 2023 Earnings: Misses Expectations

March 28, 2024 | benzinga.com

Preview: BioCardia's Earnings

March 28, 2024 | markets.businessinsider.com

BioCardia is about to announce its earnings — here's what to expect

March 28, 2024 | finance.yahoo.com

Q4 2023 BioCardia Inc Earnings Call

March 27, 2024 | benzinga.com

BioCardia: Q4 Earnings Insights

April 16, 2024 | InvestorPlace (Ad)

REVEALED: Elon Musk’s Secret A.I. Facility?

I recently shot this video outside what could be Elon Musk’s biggest secret. What’s happening inside these walls is so important that our government has declared it a matter of national security.

March 27, 2024 | globenewswire.com

BioCardia Reports Fourth Quarter and Full Year 2023 Business Highlights and Financial Results

March 20, 2024 | money.usnews.com

BioCardia Inc.

March 20, 2024 | globenewswire.com

BioCardia to Host 2023 Financial Results and Corporate Update Conference Call on March 27, 2024

March 13, 2024 | finanznachrichten.de

BioCardia, Inc.: BioCardia and StemCardia Announce Biotherapeutic Delivery Partnership

March 13, 2024 | globenewswire.com

BioCardia and StemCardia Announce Biotherapeutic Delivery Partnership

March 12, 2024 | finanznachrichten.de

BioCardia, Inc.: BioCardia Announces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure Study

March 12, 2024 | msn.com

BioCardia spikes after Medicare coverage for cell therapy trial

March 12, 2024 | globenewswire.com

BioCardia Announces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure Study

March 4, 2024 | markets.businessinsider.com

BioCardia Reports Positive Interim Results From Phase III CardiAMP Cell Therapy Heart Failure Trial

March 4, 2024 | globenewswire.com

BioCardia Reports Positive Interim Results from Phase III CardiAMP Cell Therapy Heart Failure Trial, with Compelling Data in Subgroup with Elevated NTproBNP Biomarker for Heart Failure

February 27, 2024 | finance.yahoo.com

BCDA Mar 2024 1.500 call

February 17, 2024 | finance.yahoo.com

BCDA Aug 2024 0.500 call

February 17, 2024 | finance.yahoo.com

BCDA Mar 2024 0.500 call

February 10, 2024 | msn.com

BioCardia Inc Secures Funding Through Private Placement

February 10, 2024 | msn.com

BioCardia Inc Conducts Unregistered Equity Securities Sale

February 9, 2024 | msn.com

BioCardia Launches Pivotal CardiAMP HF II Trial

February 8, 2024 | finanznachrichten.de

BioCardia, Inc.: BioCardia Announces Activation of CardiAMP Heart Failure II Phase 3 Pivotal Study Recently Approved by FDA

February 8, 2024 | finance.yahoo.com

BioCardia Announces Activation of CardiAMP Heart Failure II Phase 3 Pivotal Study Recently Approved by FDA

See More Headlines

Receive BCDA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioCardia and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/10/2021
Today: 4/15/2024
Next Earnings (Estimated): 5/08/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Current Symbol: NASDAQ:BCDA
CUSIP: N/A
CIK: 925741
Web: www.biocardia.com
Phone: (650) 226-0120
Fax: 310-861-5299
Employees: 16
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $4.00
High Stock Price Target: $4.00
Low Stock Price Target: $4.00
Potential Upside/Downside: +974.1%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.50
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.55)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-11,570,000.00
Net Margins: -2,425.79%
Pretax Margin: -2,425.79%
Return on Equity: -3,638.68%
Return on Assets: -228.55%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.40
Quick Ratio: 0.40

Sales & Book Value

Annual Sales: $480,000.00
Price / Sales: 20.74
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($0.07) per share
Price / Book: -5.32

Miscellaneous

Outstanding Shares: 26,730,000
Free Float: 20,344,000
Market Cap: $9.95 million
Optionable: Optionable
Beta: 1.47

7 Energy Stocks to Buy and Hold Forever

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

Dr. Peter A. Altman Ph.D. (Age 57)
CEO, President & Director
Comp: $515.51k
Mr. David McClung (Age 61)
Chief Financial Officer
Comp: $370.86k
Mr. Edward M. Gillis (Age 62)
Senior Vice President of Devices
Comp: $263.1k
Dr. Sujith Shetty MBBS
Chief Medical Officer and VP of Clinical & Regulatory

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

BCDA Stock Analysis - Frequently Asked Questions

Should I buy or sell BioCardia stock right now?: 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioCardia in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" BCDA shares.
View BCDA analyst ratings or view top-rated stocks.
What is BioCardia's stock price target for 2024?: 2 analysts have issued 1 year target prices for BioCardia's shares. Their BCDA share price targets range from $4.00 to $4.00. On average, they predict the company's stock price to reach $4.00 in the next twelve months. This suggests a possible upside of 974.1% from the stock's current price.
View analysts price targets for BCDA or view top-rated stocks among Wall Street analysts.
How have BCDA shares performed in 2024?: BioCardia's stock was trading at $0.6642 on January 1st, 2024. Since then, BCDA shares have decreased by 43.9% and is now trading at $0.3724.
View the best growth stocks for 2024 here.
Are investors shorting BioCardia?: BioCardia saw a decline in short interest during the month of March. As of March 31st, there was short interest totaling 535,900 shares, a decline of 46.9% from the March 15th total of 1,010,000 shares. Based on an average trading volume of 372,500 shares, the days-to-cover ratio is currently 1.4 days.
View BioCardia's Short Interest.
When is BioCardia's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our BCDA earnings forecast.
How were BioCardia's earnings last quarter?: BioCardia, Inc. (NASDAQ:BCDA) announced its earnings results on Wednesday, November, 10th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.21) by $0.05. The company had revenue of $0.82 million for the quarter, compared to analysts' expectations of $0.04 million. BioCardia had a negative trailing twelve-month return on equity of 3,638.68% and a negative net margin of 2,425.79%. During the same period in the prior year, the firm posted ($0.30) earnings per share.

When did BioCardia's stock split?: BioCardia shares reverse split before market open on Friday, November 3rd 2017. The 1-12 reverse split was announced on Thursday, November 2nd 2017. The number of shares owned by shareholders was adjusted after the market closes on Thursday, November 2nd 2017. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.
What other stocks do shareholders of BioCardia own?: Based on aggregate information from My MarketBeat watchlists, some companies that other BioCardia investors own include Arotech (ARTX), CytoDyn (CYDY), China Gold International Resources (CGG), BioSolar (BSRC), Blink Charging (BLNK), Aurcana Silver (AUNFF), RecycLiCo Battery Materials (AMY) and
When did BioCardia IPO?: BioCardia (BCDA) raised $51 million in an IPO on the week of July 20th 2015. The company issued 3,900,000 shares at $12.00-$14.00 per share. Cantor Fitzgerald & Co. acted as the underwriter for the IPO and Roth Capital Partners and Maxim Group were co-managers.
How do I buy shares of BioCardia?: Shares of BCDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:BCDA) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial